ProCE Banner Activity

A Call to Action: Identifying and Addressing Practice Gaps in the Management of Melanoma Based on the Latest Evidence

Clinical Thought

In this commentary, an expert faculty discusses recent practice‑changing clinical data in the management of melanoma, including first-line immunotherapy combinations, tumor-infiltrating lymphocyte therapy, and neoadjuvant immunotherapy.

Released: May 03, 2023

Share

Faculty

Hussein Tawbi

Hussein Tawbi, MD, PhD

Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Disclosure

Primary Author

Hussein Tawbi, MD, PhD

Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hussein Tawbi, MD, PhD: consultant/advisor/speaker: Boxer Capital, Bristol Myers Squibb, Eisai, Genentech, Iovance, Jazz, Karyopharm, Medicenna, Merck, Novartis; researcher: Bristol Myers Squibb, Dragonfly Therapeutics, Eisai, EMD Serono, Genentech, GlaxoSmithKline, Merck, Novartis, RAPT Therapeutics.